UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin

Molecular cancer therapeutics, 2011-08, Vol.10 (8), p.1394-1406

2011

Volltextzugriff (PDF)

Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors

Cancer research (Chicago, Ill.), 2008-10, Vol.68 (20), p.8322-8332

2008

Volltextzugriff (PDF)

Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non–small-cell lung, pancreatic, colon, and breast tumors

Molecular cancer therapeutics, 2006-11, Vol.5 (11), p.2676-2684

2006

Volltextzugriff (PDF)

Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor

Future medicinal chemistry, 2009-09, Vol.1 (6), p.1153-1171

2009

Volltextzugriff (PDF)

Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition

Molecular cancer therapeutics, 2007-02, Vol.6 (2), p.532-541

2007

Volltextzugriff (PDF)

A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor–dependent tumor growth in vivo

Molecular cancer therapeutics, 2007-08, Vol.6 (8), p.2158-2167

2007

Volltextzugriff (PDF)

Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity

Molecular cancer therapeutics, 2006-08, Vol.5 (8), p.2051-2059

2006

Volltextzugriff (PDF)

Knockdown of Ron Kinase Inhibits Mutant Phosphatidylinositol 3-Kinase and Reduces Metastasis in Human Colon Carcinoma

The Journal of biological chemistry, 2009-04, Vol.284 (16), p.10912-10922

2009

Volltextzugriff (PDF)

NOTCH1 signaling promotes human T-cell acute lymphoblastic leukemia initiating cell regeneration in supportive niches

PloS one, 2012-06, Vol.7 (6), p.e39725-e39725

2012

Volltextzugriff (PDF)

Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer

Nature genetics, 2011-12, Vol.43 (12), p.1219-1223

2011

Volltextzugriff (PDF)

Complexity in common diseases: big biology for all

Science translational medicine, 2010-03, Vol.2 (25), p.25cm11

2010

Volltextzugriff (PDF)

Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis

Molecular cancer therapeutics, 2007-03, Vol.6 (3), p.1143-1150

2007

Volltextzugriff (PDF)

Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions

Clinical & experimental metastasis, 2008, Vol.25 (6), p.685-693

2008

Volltextzugriff (PDF)

Bioreductive activation of mitomycin C by DT-diaphorase

Biochemistry (Easton), 1992-09, Vol.31 (34), p.7879-7885

1992

Volltextzugriff (PDF)

Novel 2-phenylquinolin-7-yl-derived imidazo[1,5- a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors

Bioorganic & medicinal chemistry, 2008-02, Vol.16 (3), p.1359-1375

2008

Volltextzugriff (PDF)

OSI-930 : A novel selective inhibitor of kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models

Cancer research (Chicago, Ill.), 2006-01, Vol.66 (2), p.1015-1024

2006

Volltextzugriff (PDF)

Imidazo[1,5- a]pyrazines: Orally efficacious inhibitors of mTORC1 and mTORC2

Bioorganic & medicinal chemistry letters, 2011-04, Vol.21 (7), p.2092-2097

2011

Volltextzugriff (PDF)

Therapeutic modulation of microRNAs

Drug discovery today. Therapeutic strategies, 2013, Vol.10 (3), p.e127-e132

2013

Volltextzugriff (PDF)

NAD(P)H : quinone oxidoreductase gene expression in human colon carcinoma cells : characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity

Cancer research (Chicago, Ill.), 1992-02, Vol.52 (4), p.797-802

1992

Volltextzugriff (PDF)

Metabolism of mitomycin C by DT-diaphorase: role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells

Cancer research (Chicago, Ill.), 1990-12, Vol.50 (23), p.7483-7489

1990

Volltextzugriff (PDF)

Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction

Cancer research (Chicago, Ill.), 1992-01, Vol.52 (1), p.108-116

1992

Volltextzugriff (PDF)

Metabolism of bioreductive antitumor compounds by purified rat and human DT-diaphorases

Cancer research (Chicago, Ill.), 1994-06, Vol.54 (12), p.3196-3201

1994

Volltextzugriff (PDF)

3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent

Bioorganic & medicinal chemistry letters, 2006-05, Vol.16 (10), p.2729-2733

2006

Volltextzugriff (PDF)

Metabolism of diaziquone by NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase): role in diaziquone-induced DNA damage and cytotoxicity in human colon carcinoma cells

Cancer research (Chicago, Ill.), 1990-11, Vol.50 (22), p.7293-7300

1990

Volltextzugriff (PDF)

1 – 25 von 183

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(164)
Mit Volltextzugriff
(159)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(117)
Life Sciences & Biomedicine
(109)
Humans
(93)
Biological And Medical Sciences
(58)
Medical Sciences
(53)
Animals
(43)
Pharmacology. Drug Treatments
(40)
Antineoplastic Agents
(37)
General Aspects
(32)
Oncology
(31)
Female
(29)
Male
(28)
Mice
(22)
Biochemistry & Molecular Biology
(18)
Adult
(17)
Antineoplastic Agents - Pharmacology
(17)
Molecular Sequence Data
(17)
Base Sequence
(15)
Cell Line
(14)
Dna Damage
(14)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial

Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin

Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors

Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non–small-cell lung, pancreatic, colon, and breast tumors

Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor

Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition

A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor–dependent tumor growth in vivo

Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity

Knockdown of Ron Kinase Inhibits Mutant Phosphatidylinositol 3-Kinase and Reduces Metastasis in Human Colon Carcinoma

NOTCH1 signaling promotes human T-cell acute lymphoblastic leukemia initiating cell regeneration in supportive niches

Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer

Complexity in common diseases: big biology for all

Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis

Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions

Bioreductive activation of mitomycin C by DT-diaphorase

Novel 2-phenylquinolin-7-yl-derived imidazo[1,5- a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors

OSI-930 : A novel selective inhibitor of kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models

Imidazo[1,5- a]pyrazines: Orally efficacious inhibitors of mTORC1 and mTORC2

Therapeutic modulation of microRNAs

NAD(P)H : quinone oxidoreductase gene expression in human colon carcinoma cells : characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity

Metabolism of mitomycin C by DT-diaphorase: role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells

Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction

Metabolism of bioreductive antitumor compounds by purified rat and human DT-diaphorases

3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent

Metabolism of diaziquone by NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase): role in diaziquone-induced DNA damage and cytotoxicity in human colon carcinoma cells

Suchergebnisse filtern